Last reviewed · How we verify

AL unit dose age specific pre-packs

Malaria Consortium, Uganda · Phase 3 active Small molecule

AL (artemether-lumefantrine) is a fixed-dose combination antimalarial that kills malaria parasites by disrupting their hemoglobin metabolism and DNA replication.

AL (artemether-lumefantrine) is a fixed-dose combination antimalarial that kills malaria parasites by disrupting their hemoglobin metabolism and DNA replication. Used for Uncomplicated Plasmodium falciparum malaria in children (age-specific formulation).

At a glance

Generic nameAL unit dose age specific pre-packs
Also known asCoartem pre-packs
SponsorMalaria Consortium, Uganda
Drug classArtemisinin-based combination therapy (ACT)
TargetParasite hemoglobin metabolism; mitochondrial electron transport
ModalitySmall molecule
Therapeutic areaInfectious Disease / Parasitology
PhasePhase 3

Mechanism of action

Artemether, a semi-synthetic artemisinin derivative, generates reactive oxygen species that damage parasite proteins and DNA. Lumefantrine, a biguanide, inhibits parasite mitochondrial function and heme polymerization. Together in age-specific pre-packs, they provide rapid parasite clearance and extended post-treatment prophylaxis, with dosing tailored to pediatric weight bands.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: